


PHARMACEUTICAL 2019

TENAX THERAPEUTICS INC. Rank 26 of 371







RealRate

PHARMACEUTICAL 2019

TENAX THERAPEUTICS INC. Rank 26 of 371

The relative strengths and weaknesses of TENAX THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of TENAX THERAPEUTICS INC. compared to the market average is the variable Other Compr. Net Income, increasing the Economic Capital Ratio by 768% points. The greatest weakness of TENAX THERAPEUTICS INC. is the variable Revenues, reducing the Economic Capital Ratio by 309% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 505% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	13,320
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,566
Liabilities, Non-Current	0
Other Assets	8.4
Other Compr. Net Income	28,271
Other Expenses	7,331
Other Liabilities	0
Other Net Income	80
Property and Equipment	8.5
Research and Development	1,239
Revenues	0
Selling, General and Administrative Expense	5,654

Output Variable	Value in 1000 USD
Assets	13,337
Liabilities	1,566
Expenses	14,224
Stockholders Equity	11,772
Net Income	-14,144
Comprehensive Net Income	-8.4
Economic Capital Ratio	173%

